Cancer Diagnosis & Biopsy in Gurugram
Almost every decision in cancer treatment rests on the diagnosis being right. This page explains why a biopsy is usually needed, what the pathologist and the molecular tests actually determine, and why a scan on its own rarely settles the question.
In summary
Short answer: A cancer diagnosis is normally confirmed on tissue, not on a scan. A biopsy provides the sample that establishes the cancer type and subtype, and supports further testing such as immunohistochemistry and molecular profiling, which together decide which treatments are appropriate.
- Who this page is for
- People awaiting a biopsy or diagnosis in Gurugram or Gurgaon, families supporting them, and anyone worried about whether a biopsy is safe
- Currently consults at
- American Oncology Institute, Gurugram
- OPD hours
- Monday to Saturday, 9:00 am - 6:00 pm
- Appointments
- +91 95606 83949
Key takeaways
- Tissue usually settles the diagnosis — imaging can show something suspicious, but rarely names it definitively.
- A biopsy does not make cancer spread — this common fear is one of the main causes of delayed diagnosis.
- Subtype changes treatment — two cancers in the same organ can need entirely different approaches.
- IHC and molecular testing refine the diagnosis further and identify targets for therapy.
- Delay has a cost — waiting for certainty that a scan cannot give usually postpones treatment, not risk.
- Related: see targeted therapy and second opinions.
Why is a biopsy needed?
Short answer: A biopsy is the removal of a small sample of tissue so it can be examined under a microscope. It answers questions no scan can settle reliably: whether a lesion is cancer at all, what type of cancer it is, and how it is likely to behave. Many suspicious findings on imaging turn out to be benign, and a biopsy is often what spares a patient unnecessary treatment. Where cancer is confirmed, the same sample usually supports the further testing that shapes the treatment plan.
Can a biopsy cause cancer to spread?
This is one of the most common concerns patients raise, and one of the most consequential, because the fear itself delays diagnosis. Biopsy techniques are designed with this risk in mind, and for the overwhelming majority of patients the benefit of establishing an accurate diagnosis far outweighs the theoretical concern. Where a particular situation calls for a specific approach, that is planned deliberately by the treating team. The far greater practical risk in most cases is the delay caused by avoiding the test.
What does the pathologist determine?
Histopathology examines the tissue architecture and cell appearance to confirm whether cancer is present and to identify its type and grade. This is more consequential than it sounds: two cancers arising in the same organ can be entirely different diseases requiring different treatment. The pathology report is therefore the foundation document of the whole treatment plan, and it is worth keeping the original report rather than only a summary.
What is IHC testing?
Immunohistochemistry, usually shortened to IHC, uses antibodies to detect specific proteins in the tissue sample. It helps confirm where a cancer originated when that is unclear, distinguishes between subtypes that look similar under the microscope, and identifies markers that directly guide treatment. Hormone receptor and HER2 status in breast cancer are the most widely known examples, where the IHC result determines whether hormonal or HER2-targeted therapy is appropriate at all.
What is NGS and molecular testing?
Molecular testing examines the genetic changes within the cancer cells themselves. Next-generation sequencing, or NGS, can assess many genes at once from a single sample. Where a targetable alteration is found, an oral targeted therapy may be appropriate in place of, or alongside, conventional treatment. Which tests are relevant depends on the cancer type: they are routine in some situations, such as non-small cell lung cancer, and not indicated in others. Testing is requested where it will change a decision, not as a matter of course.
Why is PET-CT alone not enough to start treatment?
A PET-CT is valuable for showing where disease is active and how far it extends, which is essential for staging. What it cannot reliably do is name the disease. Inflammation, infection and benign conditions can all appear active on a PET scan, and the scan cannot determine subtype, receptor status or molecular targets. Starting treatment on imaging alone therefore risks treating the wrong disease, or the right disease in the wrong way. In practice, the scan and the tissue answer different questions and are used together.
What happens between the biopsy and the treatment plan?
After the sample is taken it is processed, sectioned and examined, and further tests such as IHC or molecular profiling are added where relevant. This takes time, and the wait is often the hardest part for patients and families. Staging scans may run in parallel. Once the pathology and staging are complete, the results are reviewed together, frequently across specialties, and only then is a treatment plan finalised and discussed with you.
When is a second opinion on a diagnosis worthwhile?
It is reasonable when the diagnosis is unclear or unusual, when a rare cancer is involved, when the biopsy result does not fit the clinical picture, or before starting an intensive or irreversible treatment. A second opinion at this stage reviews the pathology and staging themselves, not just the treatment proposal, and that is exactly where a misstep would be most costly.
Consulting in Gurugram
Dr. Sandeep Ramawat currently consults at the American Oncology Institute, Gurugram. OPD hours are Monday to Saturday, 9:00 am - 6:00 pm. Please bring your biopsy report, imaging and any prior treatment records to the first visit.
Appointments: +91 95606 83949 · drsandeepramawat@gmail.com
Frequently asked questions
Short answer: Most biopsies are done under local anaesthesia and are described as uncomfortable rather than painful. The technique depends on the site and may be a needle biopsy, an endoscopic sample or a small surgical procedure, and what to expect is explained in advance.
Short answer: Basic histopathology commonly takes several days. Additional testing such as IHC or molecular profiling adds further time. The wait is genuinely difficult, and it is reasonable to ask the treating team for a realistic timeline at the point the biopsy is taken.
Generally no. A PET-CT shows where disease is active but cannot reliably establish the cancer type, subtype or molecular targets. Tissue diagnosis is normally required before systemic treatment is planned, because those details determine which treatment is appropriate.
IHC detects proteins in the tissue and helps confirm the cancer type and markers such as hormone receptors. NGS examines genetic changes within the cancer cells and can identify targetable mutations. They answer different questions and are often used together.
No. It is routine in some cancers, such as non-small cell lung cancer, and not indicated in others. Testing is requested where the result would genuinely change the treatment decision.
It is worth considering when the diagnosis is rare or unclear, when the report does not match the clinical picture, or before starting major treatment. Bring the original pathology report, blocks or slides if available, and all imaging.
Speak to Dr. Ramawat
Dr. Ramawat currently consults at the American Oncology Institute, Gurugram. Call directly or send your details on WhatsApp.